NCT06070012View on ClinicalTrials.gov

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2030

Conditions
Uveal Melanoma
Interventions
DRUG

Tebentafusp

An anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

Immunocore Ltd
All Listed Sponsors
collaborator

Immunocore Ltd

INDUSTRY

lead

Diwakar Davar

OTHER